{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:53:28Z","timestamp":1791500008957,"version":"4.3.4"},"reference-count":24,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nuklearmedizin"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>PSMA-based radioligand therapy (PSMA-RLT) for metastatic castration-resistant prostate cancer (mCRPC) is associated with nausea, vomiting, and fatigue. We evaluated whether standardized premedication with glucocorticoids and antiemetics reduces these side effects.<\/jats:p>\n                  <jats:p>In this retrospective multicentre study, 67 mCRPC patients received 322 cycles of 177Lu-PSMA-617 at three Swiss centres. All patients received 8 mg dexamethasone and 8 mg ondansetron intravenously 30 minutes before therapy. Side effects were assessed using study-specific questionnaires (195\/322 returned; 61%). Baseline symptoms were documented using EORTC questionnaires in 30 patients. Biochemical response was evaluated in 36 patients using PCWG3 criteria.<\/jats:p>\n                  <jats:p>Absolute side effect rates were: nausea within 3 days 20.9%, inter-cycle nausea 35.8%, vomiting 10.4%, and fatigue 67.2%. After correction for baseline symptoms, estimated new-onset rates were lower: 16.3%, 26.1%, 7.0%, and 6.7%, respectively. Early nausea significantly predicted inter-cycle nausea (p=0.02). Side effects followed a U-shaped pattern across cycles. No significant association was observed between side effects and PCWG3 biochemical response, though statistical power was limited.<\/jats:p>\n                  <jats:p>Absolute rates of nausea and fatigue were comparable to the VISION trial. However, new-onset rates of these two side effects were substantially lower after accounting for baseline symptoms. A protective effect of premedication with glucocorticoids and antiemetics could be the reason for this, but requires confirmation in prospective controlled studies.<\/jats:p>","DOI":"10.1055\/a-2902-0532","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T23:20:12Z","timestamp":1783552812000},"page":"303-311","source":"Crossref","is-referenced-by-count":0,"title":["Frequency and new-onset rates of nausea and fatigue in \u00b9\u2077\u2077Lu-PSMA therapy with standardized premedication"],"prefix":"10.1055","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4182-3516","authenticated-orcid":false,"given":"Wolfram A.","family":"Bosbach","sequence":"additional","affiliation":[{"name":"University of Bern, Switzerland","place":["Bern"],"department":["Inselspital, Bern, University Hospital, Department of Nuclear Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karene","family":"Sriramachandran","sequence":"additional","affiliation":[{"name":"University of Bern, Switzerland","place":["Bern"],"department":["Inselspital, Bern, University Hospital, Department of Nuclear Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasir","family":"G\u00f6zl\u00fcg\u00f6l","sequence":"additional","affiliation":[{"name":"University of Bern, Switzerland","place":["Bern"],"department":["Inselspital, Bern, University Hospital, Department of Nuclear Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Rominger","sequence":"additional","affiliation":[{"name":"University of Bern, Switzerland","place":["Bern"],"department":["Inselspital, Bern, University Hospital, Department of Nuclear Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cuzzocrea","sequence":"additional","affiliation":[{"name":"Ente Ospedaliero Cantonale, Switzerland","place":["Bellinzona"],"department":["Imaging Institute of Southern Switzerland, Clinic for Nuclear Medicine and Molecular Imaging"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabin G.","family":"Pop","sequence":"additional","affiliation":[{"name":"Cantonal Hospital Baden, Partner hospital for research and teaching of the Medical Faculty of the University of Zurich, Switzerland","place":["Baden"],"department":["Department of Nuclear Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Paone","sequence":"additional","affiliation":[{"name":"Ente Ospedaliero Cantonale, Switzerland","place":["Bellinzona"],"department":["Imaging Institute of Southern Switzerland, Clinic for Nuclear Medicine and Molecular Imaging"]},{"name":"Universit\u00e0 della Svizzera Italiana (USI), Switzerland","place":["Lugano"],"department":["Faculty of Biomedical Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene A.","family":"Burger","sequence":"additional","affiliation":[{"name":"Cantonal Hospital Baden, Partner hospital for research and teaching of the Medical Faculty of the University of Zurich, Switzerland","place":["Baden"],"department":["Department of Nuclear Medicine"]},{"name":"University of Zurich, Switzerland","place":["Z\u00fcrich"],"department":["Department of Nuclear Medicine, University Hospital Zurich"]},{"name":"ETH Zurich, Switzerland","place":["Zurich"],"department":["Department of Health Sciences and Technology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Afshar-Oromieh","sequence":"additional","affiliation":[{"name":"University of Bern, Switzerland","place":["Bern"],"department":["Inselspital, Bern, University Hospital, Department of Nuclear Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2020.101833","article-title":"Epidemiology of metastatic castration-resistant prostate cancer: A first estimate of incidence and prevalence using the French nationwide healthcare database","volume":"69","author":"NH Thurin","year":"2020","journal-title":"Cancer Epidemiol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1097\/JU.0000000000001570","article-title":"Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations","volume":"205","author":"N Shore","year":"2021","journal-title":"J Urol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"e13592","DOI":"10.1200\/JCO.2020.38.15_suppl.e13592","article-title":"Epidemiology and mortality of metastatic castration-resistant prostate cancer (mCRPC) in a managed care population in the United States","volume":"38","author":"K Wallace","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2023.1240864","article-title":"Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews","volume":"13","author":"D Leaning","year":"2023","journal-title":"Front Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","article-title":"PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-Labeled PSMA-617","volume":"57","author":"C Kratochwil","year":"2016","journal-title":"J Nucl Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"O Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1007\/s00259-022-05785-x","article-title":"Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre","volume":"49","author":"K Herrmann","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref8","first-page":"HS-10-HS-13","article-title":"Management of radiation-induced nausea and vomiting","volume":"44","author":"B Stevich-Heemer","year":"2019","journal-title":"US Pharm [Internet]"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/BF00335303","article-title":"The role of serotonin as a mediator of emesis induced by different stimuli","volume":"3","author":"A du Bois","year":"1995","journal-title":"Support Care Cancer"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/bjc.1987.177","article-title":"Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesis","volume":"56","author":"WD Miner","year":"1987","journal-title":"Br J Cancer"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","author":"JJ Zaknun","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2023.1239118","article-title":"Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer \u2013 a narrative review","volume":"13","author":"P Szponar","year":"2023","journal-title":"Front Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","article-title":"EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)","volume":"46","author":"C Kratochwil","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","article-title":"Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)","volume":"50","author":"C Kratochwil","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/pros.23974","article-title":"Influence of short-term dexamethasone on the efficacy of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"80","author":"T Derlin","year":"2020","journal-title":"Prostate"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"MS Hofman","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13550-015-0114-2","article-title":"Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study","volume":"5","author":"H Ahmadzadehfar","year":"2015","journal-title":"EJNMMI Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"12477","DOI":"10.18632\/oncotarget.7245","article-title":"Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer","volume":"7","author":"H Ahmadzadehfar","year":"2016","journal-title":"Oncotarget"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13550-025-01323-6","article-title":"Automation of 99mTc Mercaptoacetyltriglycine (MAG3) Report Writing Using a Vision Language Model","volume":"15","author":"WA Bosbach","year":"2025","journal-title":"EJNMMI Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1055\/a-2594-7085","article-title":"Evaluating the Diagnostic Accuracy of ChatGPT-4.0 in Classifying Multimodal Musculoskeletal Masses: A Comparative Study with Human Raters","volume":"198","author":"WA Bosbach","year":"2026","journal-title":"R\u00f6Fo"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1200\/JCO.1999.17.11.3461","article-title":"Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate- specific antigen working group","volume":"17","author":"GJ Bubley","year":"1999","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"HI Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"HI Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref26","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"J Cohen","year":"1988"}],"container-title":["Nuklearmedizin - NuclearMedicine"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2902-0532.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:31:42Z","timestamp":1791498702000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2902-0532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":24,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2026,10,8]]},"published-print":{"date-parts":[[2026,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2902-0532","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0029-5566","2567-6407"],"issn-type":[{"value":"0029-5566","type":"print"},{"value":"2567-6407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]}}}